INX-315 is an oral, investigational selective cyclin-dependent kinase 2 (CDK2) inhibitor. The designation was based on preclinical data as well as interim data from the ongoing phase 1/2 INX-315-01 ...

SELLAS Life Sciences Group, Inc.’s SLS share price has surged by 5.56%, which has investors questioning if this is right time ...

Herpesviruses, which cause skin and genital infections, neonatal diseases, and meningitis, can successfully persist over a ...

Cyclin D1–CDK4/6 phosphorylates GTSE1 in cancer cells, preventing its degradation and sustaining high levels across the cell cycle, which enhances proliferation and correlates with poor prognosis.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the supplemental New Drug Application (sNDA) for repotrectinib for ...

Transcription is controlled by phosphorylation of the C-terminal domain (CTD) of RNA Polymerase II (RNA Pol II). Cyclin-dependent transcriptional kinase 12 (CDK12) phosphorylates the CTD to sustain ...

本文聚焦细胞周期蛋白依赖性激酶（CDK），构建小鼠模型量化其活性。研究发现滋养外胚层（TE）细胞在着床前 CDK 活性下降，与成纤维细胞生长因子 4（FGF4）有关，且该调控机制在哺乳动物中保守，为胚胎发育研究提供新视角。 ### 研究背景 细胞周期受细胞周期 ...

For decades, cancer researchers and pharmaceutical companies have eyed cyclin-dependent kinase (CDK7) with interest due to its role as a “master regulator” of cell proliferation. CDK7 does this in two ...